Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US38341P1021
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00MVWLLM2
GOSS
Gossamer Bio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Gossamer Bio Inc
ISIN
US38341P1021
TICKER
GOSS
MIC
XNAS
REUTERS
GOSS.OQ
BLOOMBERG
GOSS US
Wed, 10.09.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.08.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the following...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.06.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced enrollment completion for the ongoing, global r...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 06.06.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter end...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 fina...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the America...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 08.04.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 13.03.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter an...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 07.03.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.02.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 03.02.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seraluti...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 28.01.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced one oral and three poster presentations related to se...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.01.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 11.11.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 07.11.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended Sep...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 07.10.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s Board o...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.08.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral presentations and a poster presentation with...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.08.2024       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended Ju...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 03.02.2023       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - February 2, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gossamer and c...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sat, 31.12.2022       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - December 30, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gossamer and...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sat, 17.12.2022       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Gossamer and...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Far...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 2, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. ("Gossamer") (NASDAQ: GOSS) The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 02.06.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - June 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 1, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS)("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - June 1, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.06.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - June 1, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sun, 31.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 31, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 pro...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 29, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 29.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 29, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 28, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 28, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 28, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Compan...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 28.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 28, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 prom...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 27, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2020       Gossamer Bio
US38341P1021

Los Angeles, California--(Newsfile Corp. - May 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 27, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 26, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 22.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 21, 2020) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 20.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 20, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 18.05.2020       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 18, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faru...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.04.2020       Gossamer Bio
US38341P1021

San Diego, California--(Newsfile Corp. - April 20, 2020) -  The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: GOSS shares.Investors, who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.co...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink